Processa appoints Sheila Gujrathi to its board effective July 28, 2026

Processa appointed Sheila Gujrathi to its board of directors, effective July 28, 2026, following the First Effective Time under the Merger Agreement.Original SEC Filing: Processa Pharmaceuticals, Inc. [ PCSA ] - 8-K - Jul. 29, 2026This is an AI-powered summary. It may contain inaccuracies. Consider…

Processa appointed Sheila Gujrathi to its board of directors, effective July 28, 2026, following the First Effective Time under the Merger Agreement.

IndividualSheila Gujrathi, M.D.

RoleDirector

Type of ChangeAppointed

Effective DateJuly 28, 2026 (effective immediately after the First Effective Time)

ReasonIn accordance with the Merger Agreement

Replacement InfoNot disclosed

Background DetailsFounder/CEO of Prana Therapies; Executive Chair/founder roles at Vidya, Lila Biologics, Generian; board roles at BlossomHill, Janux, others; former CEO/CMO roles at biopharma firms. MD; B.S. biomedical engineering; board-certified in internal medicine.

Board/Committee Role ChangesNot disclosed

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.